6.96

4.53% -0.33

Ocular Therapeutix Inc (OCUL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt OCUL? Forum Prognose

Schlusskurs vom Vortag:

$7.29

Offen:

$7.4

24-Stunden-Volumen:

4.95M

Relative Volume:

1.86

Marktkapitalisierung:

$1.53B

Einnahmen:

$52.04M

Nettoeinkommen (Verlust:

$-290.50M

KGV:

-4.7812

EPS:

-1.4557

Netto-Cashflow:

$-240.94M

1W Leistung:

-27.88%

1M Leistung:

-36.15%

6M Leistung:

-18.02%

1J Leistung:

-37.07%

1-Tages-Spanne:

$6.935

$7.425

1-Wochen-Bereich:

$6.935

$9.38

52-Wochen-Spanne:

$6.2301

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Firmenname

Ocular Therapeutix Inc

Sektor

Healthcare (1064)

Branche

Biotechnology (595)

Telefon

781-357-4000

Adresse

14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA

Mitarbeiter

325

Twitter

@OCUTX

Nächster Verdiensttermin

2026-11-03

Neueste SEC-Einreichungen

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, MRNA, REGN, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OCUL Ocular Therapeutix Inc	6.96	2.12B	52.04M	-290.50M	-240.94M	-1.4557
VRTX Vertex Pharmaceuticals Inc	504.73	133.37B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-15	Eingeleitet	Chardan Capital Markets	Buy
2025-04-08	Eingeleitet	William Blair	Outperform
2025-03-18	Eingeleitet	RBC Capital Mkts	Outperform
2025-03-11	Eingeleitet	Needham	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-06-20	Hochstufung	TD Cowen	Hold → Buy
2024-05-31	Fortgesetzt	Piper Sandler	Overweight
2024-02-09	Eingeleitet	BofA Securities	Buy
2023-04-21	Eingeleitet	Robert W. Baird	Outperform
2022-08-10	Fortgesetzt	Berenberg	Buy
2021-08-10	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-12-17	Eingeleitet	Berenberg	Buy
2020-11-13	Bestätigt	Raymond James	Strong Buy
2020-08-10	Bestätigt	H.C. Wainwright	Buy
2020-03-03	Hochstufung	Raymond James	Outperform → Strong Buy
2019-05-21	Herabstufung	Cowen	Outperform → Market Perform
2019-05-21	Bestätigt	H.C. Wainwright	Buy
2019-05-21	Herabstufung	Raymond James	Strong Buy → Outperform
2018-12-03	Bestätigt	Cantor Fitzgerald	Overweight
2018-11-15	Eingeleitet	Raymond James	Strong Buy
2018-09-07	Eingeleitet	Piper Jaffray	Overweight
2017-10-24	Eingeleitet	Guggenheim	Buy
2017-07-26	Eingeleitet	H.C. Wainwright	Buy
2017-07-12	Bestätigt	Cantor Fitzgerald	Overweight
2017-06-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Eingeleitet	Cantor Fitzgerald	Overweight
2016-11-15	Bestätigt	RBC Capital Mkts	Outperform
2016-08-11	Eingeleitet	JMP Securities	Mkt Outperform
2016-02-17	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten

Oct 01, 2026

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences - Yahoo Finance

Oct 01, 2026

Sep 29, 2026

Operating income of Ocular Therapeutix Inc – HAN:0OT - TradingView

Sep 29, 2026

RBC Capital reiterates Ocular Therapeutix stock rating on wAMD treatment potential - Investing.com Nigeria

Sep 29, 2026

ETFs Investing in Ocular Therapeutix Inc Stocks - TradingView

Sep 29, 2026

Sep 26, 2026

OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights - Stocktwits

Sep 26, 2026

Sep 25, 2026

Precision Trading with Ocular Therapeutix Inc. (OCUL) Risk Zones - Stock Traders Daily

Sep 25, 2026

Sep 24, 2026

OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits

Sep 24, 2026